Cadila: Zydus receives final approval for acyclovir ointment

Gayathri Udyawar
/ Categories: Trending, DSIJ News
Cadila: Zydus receives final approval for acyclovir ointment

Pharma major Cadila Healthcare Limited informed the exchanges that Zydus has received the final approval from the US Food and Drug Administration (USFDA) for acyclovir ointment.

 

The ointment is a generic version of GSK's Zovirax (acyclovir) Cream, 5%. Acyclovir is a synthetic nucleoside analogue active against herpes viruses. It is used to treat the outbreak of genital herpes infection. It is also used to treat non-life threatening herpes infections of the skin and around the mouth in people with weak immunity. The drug will be manufactured at the group’s topical manufacturing facility at Ahmedabad.

 

Earlier last week, the company received final approval from USFDA to market Valsartan and Hydrochlorothiazide Tablets USP used to treat high blood pressure.

 

With this, the group has 257 approvals as against 350 ANDAs filed so far.

 

Zydus Cadila is an innovative, pharma company that develops, manufactures and markets a range of healthcare therapies, globally.

 

In Tuesday's afternoon session, the stock of Cadila Healthcare was trading at Rs. 339.35 per share, up by 0.03 per cent after hitting an intraday high of Rs. 344.00 per share in the morning session.  

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR